JBS: Attractive Risk/Reward Opportunity

JBS N.V. (JBS) remains a compelling, undervalued global protein leader, despite inherent volatility and sector challenges. 4Q25 results confirm robust revenue growth, strong omniprotein model execution, and continued expansion in EMEA and legacy markets. JBS maintains a solid balance sheet with $8.2B in cash, reduced net debt, and ample liquidity to support ongoing CapEx and strategic initiatives.